Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.

Abstract

Erythropoietin (Epo), a glycoprotein hormone that is the principal regulator of erythropoiesis, is known to act also on nonhematopoietic cell types. Epo receptors have been reported on several normal and neoplastic human cells and tissues, including ovarian cancer cells. We found that long-term Epo treatment of A2780 cells resulted in the development of a… (More)

Topics

Cite this paper

@article{Solr2008ErythropoietinTO, title={Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.}, author={Peter Sol{\'a}r and Laurie Feldman and Jee Yeong Jeong and Jacqueline R Busingye and Arthur J. Sytkowski}, journal={International journal of cancer}, year={2008}, volume={122 2}, pages={281-8} }